enGene Therapeutics (ENGN) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Humacyte (HUMA) has outperformed enGene Therapeutics (ENGN) over the past year, losing 63.5% versus a loss of 75.0%. Humacyte is the larger company by market cap ($123.7 million vs $116.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | HUMA |
|---|---|---|
| Share price | $1.74 | $0.4454 |
| Market cap | $116.61M | $123.73M |
| 1-day change | -1.14% | -17.90% |
| YTD return | -80.73% | -53.65% |
| 1-year return | -75.00% | -63.49% |
| 5-year return | — | -95.94% |
| EPS (TTM) | $-2.07 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.04M |
| Net income (latest FY) | $-117.30M | $-40.83M |
| Gross margin | — | -376.05% |
| Operating margin | — | -5306.04% |
| Net margin | — | -2003.58% |
| 52-week high | $12.25 | $1.53 |
| 52-week low | $1.40 | $0.337 |
| Distance from 52-week high | -85.80% | -70.79% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +146.55% | +268.21% |
| Average volume | 1.12M | 5.36M |
| Shares outstanding | 67.02M | 277.80M |
| Employees | 81 | 184 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUMA has outperformed ENGN by 11.5 percentage points over the past year.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
ENGN vs HUMA FAQ
Which is bigger, enGene Therapeutics or Humacyte?
Humacyte (HUMA) is larger, with a market capitalization of $123.73M compared with $116.61M for enGene Therapeutics (ENGN).
Which stock has performed better over the past year, ENGN or HUMA?
HUMA returned -63.49% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Humacyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.